IRX-2 therapy with PD-L1 blockade in immunocompetent animal model.

e14149Background: Multiple therapeutic components in IRX-2 including IL-2, IL-1, IFN-γ, TNFα, IL-6, GM-CSF, and IL-8 work synergistically to activate various immune cells including T cells, dendrit...